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We report the modular formulation of ciprofloxacin-based pure theranostic nanodrugs that display enhanced antibacterial activities, as well as aggregation-induced emission (AIE) enhancement that was successfully used to image bacteria. The drug derivatives, consisting of ciprofloxacin, a perfluoroaryl ring, and a phenyl ring linked by an amidine bond, were efficiently synthesized by a straightforward protocol from a perfluoroaryl azide, ciprofloxacin, and an aldehyde in acetone at room temperature. These compounds are propeller-shaped, and upon precipitation into water, readily assembled into stable nanoaggregates that transformed ciprofloxacin derivatives into AIE-active luminogens. The nanoaggregates displayed increased luminescence and were successfully used to image bacteria. In addition, these nanodrugs showed enhanced antibacterial activities, lowering the minimum inhibitory concentration (MIC) by more than one order of magnitude against both sensitive and resistant Escherichia coli. The study represents a strategy in the design and development of pure theranostic nanodrugs for combating drug-resistant bacterial infections. nanodrugs | aggregation-induced emission | fluoroquinolones T he need for new antimicrobial therapeutics is becoming increasingly urgent due to the rapid emergence and spread of antibiotic-resistant pathogens (1, 2) . A promising strategy against drug-resistant bacteria is to revert drug resistance mechanisms, with the potential to rejuvenate large classes of previously powerful antibiotics (3) . Nanotherapeutics have in this context emerged as a new platform in drug development (4) . Compared with small-molecule drugs, which often show poor pharmacokinetic profiles and broad secondary effects, nanotherapeutics have been shown to achieve higher therapeutic efficacy and lower off-target toxicity by altering the biodistribution of drugs. The increased uptake into target cells leads to higher intracellular drug concentrations, higher therapeutic efficacy, and lower systemic toxicity. In addition, nanotherapeutics can overcome multidrug resistance by disarming the bacteria's efflux pumps which are unable to clear the nanoparticles (5) .
A relatively new form of nanotherapeutics is pure nanodrugs (PNDs), i.e., nanoparticles that consist of pure drug molecules (6) .
A key difference between PND and other nanotherapeutics is the drug-loading efficiency. Whereas PNDs are composed entirely of the drug molecule, the drug-loading efficiency for nanotherapeutics using the traditional drug carriers is significantly lower because the drug carrier is usually much larger than the small drug molecules (7) . The carrier may furthermore be more sensitive to the environment, and its subsequent degradation products can pose potential negative impacts (8) . Because PNDs are made entirely of drug molecules, they are carrier-free and can be released as the free form of the drug in a manner that results in increased activities. Examples of PNDs, primarily prepared from cancer drugs, have demonstrated enhanced antitumor efficacy due to their improved permeability and retention, enhanced bioavailability, and improved stability against enzymatic degradation (9) (10) (11) . Furthermore, because lower doses are used, side effects are decreased.
PNDs can be straightforwardly prepared by reprecipitation (12) . Although the method is in principle applicable to many drug substances, especially those having limited water solubility, some critical issues exist. Reprecipitation may not give nanoaggregates, but rather long fibers, flakes, or even large crystals. Precise control of the nanoaggregate size to below 100 nm is difficult, and suffers from batch-to-batch variations. In addition, the stability of nanoaggregates is usually poor without stabilization. These challenges are associated with the very complicated assembly process of drug-solvent and drug-drug interactions which are difficult to control (13) . Therefore, only a few empirical protocols have been reported so far, for example, covalent dimerization (9), installation of bulky hydrophobic tails (10) , and use of polymeric backbones (14) .
These challenges can potentially be addressed by applying strategies that promote stable nanoaggregate formation. One such technique is aggregation-induced emission (AIE). During the last decade, AIE has been applied to various organic compounds for the development of new luminescent materials for optoelectronic devices, sensors, biomedical imaging, and smart materials (15) . Whereas the individual AIE-active luminogens fluoresce poorly in solution, the emission increases markedly upon their aggregation in response to restricted molecular motions. Such nanosized aggregates are frequently obtained using propeller-shaped molecules (16) , in contrast to planar entities that are prone to form crystalline seeds and further grow into bulk crystals (17, 18) . Furthermore, the restriction of
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Encouraged by these observations, we designed a type of PNDs based on AIE-active fluoroquinolones. Fluoroquinolones such as ciprofloxacin are among the most prescribed antibiotics for the treatment of various infections (24) . Their broad-spectrum efficacy is associated with the mechanism of action, which is the inhibition of DNA replication and repair (25) . The emergence of fluoroquinoloneresistant microorganisms has long been observed and is partly attributed to the overuse of quinolone antibiotics (26) . Resistance to fluoroquinolones generally arises from mutations of target enzymes that reduce the susceptibility to the drug, or by a reduction of the intracellular drug concentration (27) . The latter is achieved through limiting drug influx, e.g., by expressing fewer porins, and/or through drug extrusion by expressing multidrug efflux pumps.
Most fluoroquinolones are electron donor-acceptor compounds with the piperazinyl group serving as the electron donor and 4-oxoquinoline-3-carboxylic acid as the electron acceptor in the neutral and zwitterion forms. In organic solvents like acetonitrile, fluoroquinolones are weakly fluorescent, owing to the high nonradiative rate constants which deactivate the singlet excited state through intramolecular charge transfer (28) . We hypothesized that by forming nanoaggregates, the intramolecular motion, a process that promotes nonradiative relaxation pathway, would be restricted (15) . This would open up the radiative pathway, leading to the enhanced fluorescence emission allowing the nanoaggregates to be used as imaging agents. In this proof-of concept study, we designed and synthesized propeller-shaped structures consisting of a fluoroquinolone such as ciprofloxacin, a perfluoroaryl group, and a phenyl group through a straightforward protocol. We show that these compounds can be prepared into antibiotic nanodrugs that served as both imaging agents and therapeutic drugs.
Results and Discussion
The ciprofloxacin derivatives were synthesized from readily accessible perfluoroaryl azides, phenylacetaldehyde, and ciprofloxacin by stirring them in acetone at room temperature ( Fig. 1 ).
Phenylacetaldehyde and ciprofloxacin initially formed the enamine in situ, which then reacted with perfluoroaryl azides to give the amidine products. This unique reactivity of perfluoroaryl azides is due to their highly electron-deficient nature, which allows these electrophilically activated azides to undergo cycloaddition with enamines at room temperature without any catalysts (29, 30) , and also with other dipolarophiles and nucleophiles (31) (32) (33) . Ciprofloxacin is sparingly soluble in common organic solvents. However, the ciprofloxacin conjugates showed much improved solubility in organic solvents and enabled efficient separation by flash column chromatography or recrystallization. This reaction is efficient and modular, allowing the introduction of the perfluoroaryl and phenyl moieties to ciprofloxacin by a straightforward protocol.
The derivatization of ciprofloxacin showed minimal impact on its absorption, but caused large changes in the fluorescence emission. In the dissolved state, strong emission from derivatives 5-6 (Φ f = 19-26%, SI Appendix, Table S1 ) was observed in dry THF and dichloromethane (DCM) compared with ciprofloxacin (Φ f = 2-9%). These are among the strongest quinolone fluorophores reported (34, 35) . The electron-withdrawing amidine decreases the electrondonating capability of the outer piperazinyl nitrogen, similar to the effect of acylation (28) . This results in blocking of the photoinduced electron-transfer process from the outer piperazinyl nitrogen to the fluoroquinolone ring, which is the most efficient energy-dissipation pathway of ciprofloxacin. In polar solvents, such as acetonitrile, methanol, and water, derivatives 5-7 emitted faintly. As the polarity of the solvent increased from toluene to acetonitrile, the emission peak gradually red-shifted from 400 to 460 nm. The red shift and decrease in emission with the increase of solvent polarity (SI Appendix, Figs. S1 and S2) is indicative of a twisted intramolecular charge-transfer process upon photoexcitation from the donor (piperazinyl ring) to the acceptor (fluoroquinolone ring) (34, 35) , a process that is stabilized and promoted by polar solvents, however, susceptible to nonradiative quenching (36) (37) (38) .
Compounds 5-6, 8-9, and 11 displayed behavior as AIE-active luminogens (SI Appendix, Fig. S3 ). For example, compound 5 showed weak fluorescence (Φ f ∼ 1.0%) in acetonitrile with an emission maximum at 465 nm ( Fig. 2A ). Addition of water showed polarity-induced quenching, and decreased the absorption at λ max = 280 nm (Fig. 2C ). However, when the water content increased to 80 vol %, the emission started to increase together with a blue shift to 457 nm. The maximal fluorescence intensity was observed at 90 vol % (Φ f = 12%), which was 12-and 30-fold stronger than its solution in pure acetonitrile or 10 vol % water/ MeCN, respectively (Fig. 2B ). In addition, broad tails appeared and the absorption intensity increased with water due to Mie scattering, indicating the formation of nanoaggregates which was also confirmed by scanning electron microscopy (SEM, Fig. 2D ). These observations are consistent with many other AIE-active luminogens having donor-acceptor structures (21, 22, 37, (39) (40) (41) , where the aggregation hampers the intramolecular motion between the donor and the acceptor, hence leading to enhanced fluorescent emission as well as a blue shift in the emission peak (15) . Spherical nanoaggregates were observed at high water content (≥99 vol %) ( Fig. 3) . These nanoaggregates were amorphous as confirmed by diffraction (Fig. 3A, Inset) . The nanoaggregates could be prepared reproducibly and displayed relatively homogeneous morphology and emission properties. The higher the water content, the smaller the nanoaggregates (SI Appendix, Table  S2 ) (17) . Screening of organic solvents showed that the size of the nanoaggregates decreased with increasing dielectric constant (SI Appendix, Fig. S4 ) (42) . This provides a convenient way to control the size of the ciprofloxacin nanoaggregates. In the case of compound 5, it precipitated into 40-60-nm nanoaggregates in DMF, MeCN, acetone, and DMSO, which were much smaller than the 90-nm nanoaggregates from THF [measured by dynamic light scattering (DLS); SI Appendix, Table S2 ]. The nanosized nanoaggregates also exhibited high storage stability. For example, compound 5 (d ∼ 60 nm) showed no significant change in size over 2 mo at 4°C (Fig. 3G) . Other derivatives were also evaluated (SI Appendix, Table S2 ), and spherical amorphous nanoaggregates were similarly observed ( Fig. 3 and SI Appendix, Fig. S5 ). These nanoaggregates have negative zeta potential from −25 mV to −40 mV, likely due to the carboxylate groups on the quinolone ring being exposed at the particle-solution interface (10) .
Crystal structures were collected to investigate the intermolecular interactions in these compounds. Compound 5 adopts a more tightly packed antiparallel dimer configuration (Fig. 4A) . The pentafluoroaryl and fluoroquinolone groups are partially in the face-toface orientation, with the closest distance of 3.08 Å. The phenyl groups take a coplanar arrangement, with no additional interactions identified. The crystal structure of compound 5 prepared from THF adopts a similar dimer configuration as from acetonitrile, but shows a different amidine torsion angle in the amidine moiety (SI Appendix, Fig. S6 ). When replacing F at the p position on the perfluorophenyl ring in 5 with a methoxy (OMe) group, the resulting compound 6 exhibits a more extended configuration (Fig. 4B) , showing antiparallel face-to-face stacking between the two pentafluoroaryl groups (∼3.4 Å) and the two fluoroquinolone groups (∼3.5 Å), and weaker interactions between the two phenyl rings (∼4.2 Å) (43) . The intermolecular interactions efficiently restrict the intramolecular motions in the nanoaggregates, contributing to the enhanced emission in the nanoaggregates by slowing down the intramolecular charge transfer.
Among all propeller-type ciprofloxacin derivatives, compound 5, having a pentafluorophenyl group, yielded spherical nanoaggregates with the smallest size, high stability, and strong AIE enhancement (SI Appendix, Table S2 ). Compound 11, a norfloxacin derivative, also yielded nanoaggregates [d ∼ 64 nm, polydispersity index (PDI) = 0.21] comparable to compound 5 (d ∼ 60 nm, PDI = 0.24). Compound 12, lacking the quinolone structure, could form nanoaggregates with stability up to 4 d, albeit displaying a much larger size (d = 232 nm, PDI = 0.11). In contrast, compound 10, in which the phenyl ring was replaced by H, did not yield measurable nanoaggregates, supporting the hypothesis that a propeller shape is essential for nanoaggregate formation. Because many drugs have amine functionality, this straightforward protocol of introducing both perfluoroaryl and phenyl groups constitutes a general strategy for the formulation of PNDs.
These nanoaggregates showed fluorescent properties with up to 11% quantum yield (SI Appendix, Table S2 ). The ability of these nanoaggregates in bioimaging was tested on bacteria. In the example shown in Fig. 5 , a suspension of nanoaggregates from compound 5 was incubated with Escherichia coli (E. coli) ORN178. To maintain cell viability, the concentration of nanoaggregates (0.28 μM) was lower than the minimum inhibitory concentration (MIC) ( Table 1) , and the incubation time was much shorter (4 h vs. 16-18 h) . Subsequently, the nanoaggregates were removed by centrifugation and the bacteria were redispersed for imaging. Fluorescence from the nanoaggregates of compound 5 was observed ( Fig.  5A) , some at the locations where the bacteria were present (Fig. 5  B-D) . Fig. 5E shows one bacterium with a nanoaggregate attached. At the location where the nanoaggregate was present [region of interest (ROI1) Fig. 5F ], the fluorescence signals were dominated by the emission from the nanoaggregate (410-600 nm, Fig. 5G ), which can be distinguished from the weak autofluorescence from the bacterium (480-550 nm, Fig. 5 I and J) . Residual fluorescence from compound 5 was observed on the bacterium in regions without the nanoaggregate (ROI2), likely due to the disassembly of the nanoaggregate during incubation. The colocalization of nanoaggregates on the bacteria suggests the potential for an increase in the concentration of drug molecules in the vicinity of the bacteria compared with the soluble drugs, paving the way for enhanced antimicrobial activity of these nanoaggregates.
To test whether the nanoaggregate formulation leads to enhanced antibacterial activities, these nanoaggregates and the corresponding compounds in the soluble form were tested against several strains of E. coli [American Type Culture Collection (ATCC) 25922, ORN 178, and ORN 208]. The compounds in the nanoaggregate form generally resulted in lower MICs than the soluble forms (Table 1) . For example, compound 5 has an MIC of 233 μM in the soluble form against E. coli ORN 178, whereas the nanoaggregates of compound 5 (39-74 nm) gave an MIC of 1.25-8.7 μM, up to two orders of magnitude lower. Similar results were observed for other ciprofloxacin derivatives, for example compounds 6-8, showing lower MICs for the nanoaggregates in comparison with their soluble forms. Enhanced antibacterial activity was also observed for E. coli ORN 208 (SI Appendix, Table  S3 ), a nalidixic acid (Nal)-resistant variant from E. coli K-12 (44) . These data demonstrate that the PND strategy could indeed lead to enhanced antibacterial activity of the free drug.
In summary, we report a modular formulation of theranostic PNDs based on fluoroquinolones. The resulting fluoroquinolone derivatives formed nanoaggregates with enhanced fluorescent emission. The AIE effect was attributed to the packing of the propeller-shaped structures in the aggregated form, which restricted the intramolecular motions. The nanoaggregates were successfully used as luminescent organic dots to image bacteria. Furthermore, these nanoaggregates showed aggregation-enhanced antibacterial activity. Thus, the PNDs lowered the MIC against E. coli by more than one order of magnitude. The enhanced bacterial-killing efficiency of PNDs can be in part attributed to the colocalization of the nanoaggregates with the bacterium (Fig. 5 ) leading to a higher local drug concentration, and enhanced uptake of drug molecules when delivered in the nanosized particles (45) . The present study represents a strategy in the design and development of antimicrobial therapies for combating drug-resistant bacterial infections. It can be furthermore used in combination with other strategies, for example, the prodrug approach to modulate drug solubility and activity, to further enhance the efficiency of the PNDs.
Materials and Methods
Synthesis of Ciprofloxacin Derivatives. The following describes the synthesis of compound 5. All other compounds were prepared following similar procedures. Pentafluorophenyl azide (414 mg, 2 mmol), phenylacetaldehyde (400 mg, 4 mmol), and ciprofloxacin (546 mg, 1.65 mmol) were mixed with acetone (100 mL), and stirred at room temperature until the solution became clear. After acetone was removed, the crude solid was dissolved in DCM, and washed with aqueous HCl (0.5 M). After evaporation of DCM, the crude product was purified by flash column chromatography over silica gel (95:5 DCM/methanol, R f = 0.4) to yield compound 5 as a pale-yellow solid (860 mg, 85%). 1 Preparation of Drug Nanoaggregates. Typical procedure: To an 8 mL vial containing Millipore water (5.94 mL), a stock solution of compound 5 in MeCN or DMSO (60 μL, 1 mM) was injected using a micropipette while shaking. After addition, the vial was hand-shaken rapidly for 20 s. Other nanoaggregates were prepared following the same protocol. DLS measurements were performed directly from the suspensions. For transmission electron microscopy (TEM) analysis, the nanoaggregate suspension was n, number of assays, each performed in duplicates or triplicates. In the case of nanoaggregates, the concentration refers to that of the molecule rather than the nanoaggregates. *Calculated from the averages of MIC free and MIC aggregate . † The particle size was measured by DLS, obtained from the main peak by intensity. Samples prepared from different batches having the particle size falling in the range were tested. ‡ 1 assay extrapolated (48) . # 4 assays extrapolated (48) . § 2 additional assays showing MIC greater than the highest concentration, thus the upper limit is slightly underestimated.
{ 1 additional assay showing MIC greater than the highest concentration, thus the upper limit is slightly underestimated.
dropped onto a copper grid and quickly dried. For SEM analysis, the suspension was dropped onto an Al substrate and quickly dried under vacuum.
Imaging Bacteria. E. coli ORN 178 were incubated overnight in Mueller-Hinton broth at 37°C with shaking at 250 rpm. The bacteria were pelleted (6,500 rpm, 4,000 × g, 15 min) and redispersed in pH 7.4 PBS to an OD 620 of 0.070 (∼10 8 cfu/mL). A 0.400 mL suspension of compound 5 aggregates prepared from 90 vol % water/acetonitrile (100 μM) was added to a 1.00-mL aliquot of the bacteria suspension, and the mixture was incubated at 37°C for 4 h while shaking at 500 rpm. The mixture was then centrifuged (6,500 rpm, 4,000 × g, 15 min); the supernatant was discarded and the pellets redispersed in pH 7.4 PBS buffer (1.00 mL). An aliquot of the suspension (0.100 mL) was spread on a glass-bottom dish. Confocal fluorescence microscopy images were collected using a Zeiss LSM 780 confocal microscope (Carl Zeiss) with a Plan Apochromat 63×/1.4 oil DIC M27 objective and a 32-channel GaAsP spectral detector. The microscope was focused on the surface of the glass-bottom dish where live bacteria transiently sedimented before they migrated away. A 405-nm excitation source was used for all imaging experiments.
MIC Assays. MIC was determined by broth microdilution (46, 47) , with slight modifications. Liquid cultures of bacteria (E. coli ATCC 25922, E. coli ORN 178, E. coli ORN 208) were grown in log phase and diluted to 10 6 cfu/mL The aqueous nanoaggregates suspension was diluted sequentially with water. Aliquots of the aggregate suspension (50 or 100 μL) was mixed with the equal volume of bacterium suspension in a 96-well plate (in duplicates or triplicates). For the MIC assay of the free drugs, the compounds were first dissolved in MeCN, and further diluted in PBS buffer (pH = 7.4) to give a maximum final concentration of 30 vol % organic solvent. The plates were incubated at 37°C for 16-18 h. A resazurin solution (10 or 20 μL of 0.01 w/vol % to wells with 100 or 200 μL drug/bacteria mixture, respectively) was added to each sample, and the plates were incubated for 2 more hours, whereafter the color change was noted. The MICs obtained by color change corresponded to those from turbidity measurement (47) , except where free drug precipitated. For extrapolation of partial growth inhibition by Gompertz function (48), the turbidity was recorded.
